C-health Research

We believe that clinical research is key to improving the lives of our patients and all Albertans. 

C-health Research

We believe that clinical research is key to improving the lives of our patients and all Albertans. 

About C-health Research

C-health Research is a division of the C-health network of specialist clinics. Since inception in 2012, this division has participated in more than 50 industry-initiated clinical trials. With a team of more than 25 specialists, healthcare professionals and other highly educated and experienced research personnel, the C-health Research team participates in clinical research across Alberta with locations in Calgary, Edmonton, and Sherwood Park.

Who Benefits from Research?

Patients – Patients who participate in clinical research directly benefit from their involvement because it provides them access to effective and novel therapies or devices that would otherwise be unavailable to them, due to financial or other circumstances. 

Professionals – Professionals who participate in clinical research gain first-hand experience and knowledge with new therapies or devices, allowing them to stay on the cutting edge and practice early adoption of new treatments.

Community – Albertans gain access to novel therapies and medical devices not yet covered by provincial health insurance. Further, Canadians benefit from local clinical research programs, as Health Canada requires rigorous evaluation of new treatments prior to granting approval for use in clinical practice. Often these medications have already been accepted and approved in neighboring countries. Without clinical research, many of these novel and efficacious therapies and devices would never hit the shelves and become available to Canadians.

Research Areas

C-health Research primarily focuses on clinical research in the medical areas of diabetes, obesity, and cardiovascular disease. Our well-established and highly recognized Standard Operating Procedures (SOPs) allow us to continue exploring different areas of research to further knowledge and innovation within the community, province, and country!


Recognizing the importance of diabetes research towards improving the health of people affected by the disease, C-health Research, has continued to participate in diabetes research since 2012. Diabetes is a chronic condition often requiring treatment in addition to lifestyle interventions. Through our clinical trials we have contributed towards the prevention, treatment, management, and possible future cure of diabetes. C-health Research is particularly proud of its contribution to the pharmacotherapy landscape accessed by Canadians today, with its involvement in important trials investigating the safety and efficacy of novel medication classes. 


In 2015, the Canadian Medical Association recognized obesity as a chronic disease. Obesity is caused by complex factors, including the interaction of genetics, biological systems, and one’s environment – far more complex than previously acknowledged. This has led to a shift in the obesity management paradigm, away from the previous “eat less, move more” concept, towards an inclusive, sustainable, comprehensive, life-long approach using tools such as cognitive behavioral therapy, patient education, and medical intervention to improve the health of those living with overweight or obesity. C-health Research recognizes Obesity Canada’s definition of obesity as: a progressive chronic disease, which is characterized by abnormal or excessive adipose tissue that impairs health – not an issue of will power! 

At C-health Research, we are working to address obesity by investigating novel pharmacotherapies, developing, and evaluating sustainable obesity support programs, and promoting further education on the complexity of obesity within our community.

Cardiovascular Disease

Cardiovascular disease (CVD) is a collection of diseases and conditions, such as atherosclerosis, angina, coronary artery disease (CAD), myocardial infarction (MI), congestive heart failure (CHF), arrhythmias, and atrial fibrillation, that cause cardiovascular problems. In recognition of the significant burden of disease associated with CVD, C-health Research works to investigate and evaluate interventions to promote prevention, improve treatment, and enhance the management of CVD in Canadians.

Recently Published Trials
  1. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled, and active-controlled, dose-finding phase 2 trial
  2. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity
  4. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Actively Recruiting Trials

1. Protocol Title: ZEUS – Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

2. Protocol Title: AT-001-2001- Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients with Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure)

3. Protocol Title: PREFER-BASAL – A Prospective, Observational Study of the Effectiveness of FreeStyle Libre / FreeStyle Libre 2 in People with Type 2 Diabetes using Basal Insulin

Interested in participating in research? Contact our Research team at 403-705-3636.